The estimated Net Worth of Christopher J. Tovey is at least $1.6 Milion dollars as of 5 July 2022. Mr. Tovey owns over 5,209 units of GW Pharmaceuticals stock worth over $1,026 and over the last 6 years he sold GWPH stock worth over $833,440. In addition, he makes $763,064 as Chief Operating Officer at GW Pharmaceuticals.
Christopher has made over 5 trades of the GW Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 5,209 units of GWPH stock worth $833,440 on 5 July 2022.
The largest trade he's ever made was exercising 200,736 units of GW Pharmaceuticals stock on 7 May 2019 worth over $14,052. On average, Christopher trades about 32,831 units every 96 days since 2019. As of 5 July 2022 he still owns at least 14,663 units of GW Pharmaceuticals stock.
You can see the complete history of Mr. Tovey stock trades at the bottom of the page.
Christopher John Tovey serves as Chief Operating Officer of the Company. Mr. Chris Tovey has served as our Chief Operating Officer since October 2012. Prior to joining the Company, Mr. Tovey was at UCB Pharmaceuticals (“UCB”) from 2006 to 2012. In his last role there, Mr. Tovey was the Vice President of Global Marketing Operations where he was responsible for worldwide marketing activities on a portfolio of UCB products including Keppra®, an anti-epileptic drug generating over €2.0 billion in annual sales. Previous experience and roles at UCB included a number of multi-country product launches including Vimpat®, an anti-epileptic drug, Managing Director Greece and Cyprus, and leader of all UCB activities on the orphan narcotic medication Xyrem®, which is used in the treatment of narcolepsy. Mr. Tovey previously spent 18 years at GlaxoSmithKline plc (“GSK”) in senior commercial roles in both the European and U.K. organizations. These roles included Director Commercial Strategy Distribution Europe, Director European Vaccine Therapy, Director Commercial Development U.K., Director Vaccines Business Unit U.K. and Business Unit Manager Oncology U.K. While at GSK, Mr. Tovey worked across a wide range of therapeutic areas including neurology, infectious diseases, oncology, diabetes, respiratory, gastroenterology and immunology. Mr. Tovey is also currently a non-executive director of CanImGuide Therapeutics AB, an early-stage biopharmaceutical company developing new treatments for cancer through inhibition of LFA-1 receptor antagonism.
As the Chief Operating Officer of GW Pharmaceuticals, the total compensation of Christopher Tovey at GW Pharmaceuticals is $763,064. There are 5 executives at GW Pharmaceuticals getting paid more, with Justin Gover having the highest compensation of $7,864,300.
Christopher Tovey is 54, he's been the Chief Operating Officer of GW Pharmaceuticals since 2017. There are 9 older and 3 younger executives at GW Pharmaceuticals. The oldest executive at GW Pharmaceuticals is William Waldegrave, 73, who is the Non-Executive Independent Director.
Christopher's mailing address filed with the SEC is 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, L2, .
Over the last 6 years, insiders at GW Pharmaceuticals have traded over $60,899,192 worth of GW Pharmaceuticals stock and bought 7,200 units worth $48,960 . The most active insiders traders include Geoffrey W Dr Guy, James Noble a Justin D. Gover. On average, GW Pharmaceuticals executives and independent directors trade stock every 10 days with the average trade being worth of $8,011. The most recent stock trade was executed by Douglas B. Snyder on 6 April 2021, trading 8,400 units of GWPH stock currently worth $152,208.
GW Pharmaceuticals executives and other stock owners filed with the SEC include: